Becton, Dickinson and Company BDX, popularly known as BD, recently announced the commercial launch of a new single-cell research tool, BD Rhapsody ATAC-Seq Assay. The tool is intended to help scientists better understand how the molecular machinery within a cell function and how it regulates changes in a cell that can lead to cancer and other diseases. More on the News Single-cell studies of various areas of health and disease are currently being conducted by researchers worldwide utilizing novel methodologies. With the recently launched BD Rhapsody Single Cell ATAC-Seq (assay for transposase-accessible chromatin using next-generation sequencing) Assay, researchers can analyze the single-cell epigenome, such as the collection of chemical marks, or epigenetic changes, on a single cell DNA that holds important hints about disease mechanisms. Researchers will be able to better track and comprehend how environmental influences affect DNA and, consequently, cell activity with the addition of an epigenomic layer view. Scientists can better understand how diseases originate and use this knowledge to create successful medicines by learning more about DNA. The Rhapsody ATAC-Seq Assay, along with other recently introduced BD single-cell assays, forms part of BD's extensive and expanding portfolio of single-cell multiomics solutions, allowing customers to gain a deeper understanding of even rare cells, which are frequently the 'key culprits' in pathologies such as infectious diseases and cancer. The BD Rhapsody ATAC-Seq Assay, BD Rhapsody TCR/BCR Next Multiomic Assay, and BD Rhapsody Intracellular CITE-Seq Assay are currently available for purchase worldwide and are intended to be utilized with the BD Rhapsody Single-Cell Analysis System, a delicate, microwell-based tool for single cell research. More on BD’s Product Launches BD has launched several products in recent times, which has enabled it to solidify its foothold worldwide. In April, BD announced the global commercial release of the three- and four-laser additions to the BD FACSDiscover S8 Cell Sorter family, which complement the five-laser instrument launched in 2023 and provide scientists greater access, options and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs. In March, BD’s Medical segment’s Medication Delivery Solutions business unit announced that it is further increasing domestic production of syringes to support U.S. healthcare needs, following the latest FDA safety communication regarding certain non-BD plastic syringes. Industry Prospects Per a report by Grand View Research, the global single-cell analysis market size, which was valued at $4.34 billion in 2023, is expected to witness a growth rate of 18.7% from 2024 to 2030. This growth can be attributed to the expanding application scope in disease diagnosis and drug discovery & development, the lucrative growth of sequencing technology, technological innovations in single-cell analysis & cell isolation, and the rising incidence of cancer. Notable Developments Recently BD announced a definitive agreement to acquire Edwards Lifesciences Critical Care product group (Critical Care). The transaction is expected to close before the end of the calendar year 2024, subject to customary regulatory reviews and closing conditions. In May, the company received the FDA’s approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval is expected to enable women to self-collect vaginal specimens for HPV testing in a healthcare setting, including non-traditional locations such as retail pharmacies or mobile clinics. Price Performance For the past six months, BDX’s shares have plunged 4.7% against the industry’s rise of 1%. The S&P 500 increased 14.8% in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Other Stocks to Consider BDX carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks in the broader medical space that have announced quarterly results are DaVita DVA, Ecolab ECL and Universal Health Services UHS. DaVita, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 44% compared with the industry’s 20.4% rise in the past year. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year. Universal Health Services has an Earnings ESP of +2.91% and a Zacks Rank #2 at present. UHS has an estimated earnings growth rate of 30.5% for 2024. UHS’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.12%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ecolab Inc. (ECL):Free Stock Analysis Report Becton, Dickinson and Company (BDX):Free Stock Analysis Report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...